A Phase 4 interventional study of Kabiven® and Compounded standard parenteral nutrition in Malnutrition, sponsored by Fresenius Kabi. Withdrawn at 2 sites in United States. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2019-09-04.
Sponsored by Fresenius Kabi · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Malnutrition by Fresenius Kabi — 4 open to participants now, 4 under way, none of them phase 3. Malnutrition · Fresenius Kabi.
Among the 13 studies in Malnutrition by Fresenius Kabi, this one is one of 2 that started in 2018, is one of 5 in phase 4, and was the 3rd registered.
1,278 studies on the registry are indexed under Malnutrition; 232 are open to participants now.
Browse Malnutrition studies →4 of the 13 studies in Malnutrition by Fresenius Kabi are open now, in 2 countries. Recruiting first, the newest first:
Fresenius Kabi Taiwan Ltd. · Sites in Taiwan
Ages 18+
Fresenius Kabi Taiwan Ltd. · Sites in Taiwan
Ages 18+
Fresenius Kabi · Sites in United States
Ages 1 days–17 yrs
Fresenius Kabi · Sites in United States
Ages 1 mo–17 yrs
By country, each count listing its studies:
Of the 151 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 45 (30%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.
This study: 2 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2018.
Median enrollment 20 across the 9 interventional studies, 315 across the 4 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.
1 of the studies in Malnutrition by Fresenius Kabi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06049680Fresenius KabiSafety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Malnutrition by Fresenius Kabi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Demonstrate the safety and efficacy of Kabiven compared to standard parenteral nutrition (PN) administered via central vein in pediatric patients (2 to 16 years of age) requiring PN to meet nutritional needs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Kabiven is a sterile, hypertonic emulsion in a three chamber container. The separate chambers contain either amino acids with electrolytes, dextrose, or lipid injectable emulsion.
Drug: Kabiven®
The control drug will be compounded for each individual patient as prescribed by the physician. Compounding will be performed according to normal hospital procedure which meets the requirements of the United States Pharmacopeial Convention (USP) \<797\> "Pharmaceutical Compounding-Sterile Preparations".
Drug: Compounded standard parenteral nutrition
Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories. The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours. Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Also known as: Kabiven® for intravenous use (investigational drug)
Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories. The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours. Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Also known as: Compounded standard parenteral nutrition (control drug)
All adverse events (AE)
Time frame: After randomization until Day 9
Vital signs: blood pressure
Time frame: Day 1 - 9
Vital signs: heart rate
Time frame: Day 1 - 9
Vital signs: body temperature
Time frame: Day 1 - 9
Vital signs: respiratory rate
Time frame: Day 1 - 9
Vital signs: saturation of peripheral oxygen (spO2)
Time frame: Days 1-9
Urine volume
Time frame: Days 1-9
Change from baseline urea nitrogen on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline alanine aminotransferase (ALT) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline aspartate aminotransferase (AST) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline direct bilirubin on days 2, 5 and 9 on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline total bilirubin on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline gamma-glutamyl transpeptidase (GGTP) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline alkaline phosphatase (ALP) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline creatinine on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline electrolytes (sodium, potassium, magnesium, calcium, chloride, phosphate) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline osmolarity on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline pH on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline glucose on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline triglycerides on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline cholesterol on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline lipase on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline amylase on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline total protein on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline c-reactive protein (CRP) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline white blood cells (WBC) count on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline platelet count on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline red blood cells (RBC) count on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline hemoglobin (hgb) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline Hematocrit (hct) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Change from baseline international normalized ratio (INR) on days 2, 5 and 9
Time frame: Days 1, 2 (or if not done: Day 3), 5, 9
Nosocomial infection
Number of health care associated infections
Time frame: After randomization until Day 9
Need for renal replacement therapy
Time frame: Days 1-9
Duration of renal replacement therapy
Time frame: Days 1-9
Need for mechanical ventilation
Time frame: Days 1-9
Duration of mechanical ventilation
Time frame: Days 1-9
Change from baseline body weight on days 5 and 9
Time frame: Days 1, 5, 9
Change from baseline albumin on days 5 and 9
Time frame: Days 1, 5, 9
Change from baseline prealbumin on days 5 and 9
Time frame: Days 1, 5, 9
Change from baseline transferrin on days 5 and 9
Time frame: Days 1, 5, 9
Change from baseline alpha linolenic acid on days 5 and 9
Time frame: Days 1, 5, 9
Change from baseline linoleic acid on days 5 and 9
Time frame: Days 1, 5, 9
Change from baseline arachidonic acid on days 5 and 9
Time frame: Days 1, 5, 9
Change from baseline eicosatrienoic (mead) acid on days 5 and 9
Time frame: Days 1, 5, 9
Change from baseline triene/tetraene ratio (Holman index) on days 5 and 9
Time frame: Days 1, 5, 9
Start is estimated for Mar 2018; primary completion for Mar 2020, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.